Context Therapeutics (CNTX) Common Equity (2020 - 2026)

Context Therapeutics has disclosed Common Equity across 7 years of filings, most recently posting $52.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $52.2 million, down 42.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.2 million (down 42.62% YoY), and the FY2025 annual result was $60.5 million, down 36.52% from the prior year.
• Common Equity came in at $52.2 million for Q1 2026 at Context Therapeutics, down from $60.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $101.1 million in Q2 2024 to a low of $8.4 million in Q1 2024.
• The 5-year median for Common Equity is $45.4 million (2022), against an average of $52.4 million.
• Across the five-year window, Common Equity slumped 70.61% in 2024 and jumped 977.58% in 2025, its largest moves.
• Context Therapeutics' Common Equity stood at $34.8 million in 2022, then plunged by 65.85% to $11.9 million in 2023, then surged by 702.51% to $95.3 million in 2024, then slumped by 36.52% to $60.5 million in 2025, then retreated by 13.68% to $52.2 million in 2026.
• The last three Common Equity figures came in at $52.2 million (Q1 2026), $60.5 million (Q4 2025), and $73.2 million (Q3 2025), per Business Quant data.